Indian Pharma Q3 Outlook: Domestic Growth Offsets US Sales and Margin Pressures

Indian pharmaceutical companies face mixed Q3 results as US sales decline due to loss of Revlimid patent exclusivity and pricing pressures. While US generics and specialty launches offer some growth, margins are expected to be muted with increased costs and competition. Domestic formulations and segments like injectables and custom synthesis show steady growth, supporting companies such as Sun Pharma, Dr Reddy's, and Aurobindo Pharma amid challenges in the US market.